Metabolism and disposition of a selective α7 nicotinic acetylcholine receptor agonist in humans

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1188-1195

  Shaffer, Christopher L ^a   Gunduz, Mithat ^a   Scialis, Renato J ^a   Fang, Annie F ^a,b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Department of Metabolism and Pharmacokinetics ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYTOCHROME P450 2D6; FLAVINE ADENINE NUCLEOTIDE; FLAVINE ADENINE NUCLEOTIDE CONTAINING MONOOXYGENASE 1; FLAVINE ADENINE NUCLEOTIDE CONTAINING MONOOXYGENASE 3; GLUCURONIDE; N 1 AZABICYCLO[2.2.2]OCT 3 YLFURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; NITROGEN OXIDE; PYRIDINE DERIVATIVE; QUINUCLIDINE; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG STABILITY; EXPERIMENTAL STUDY; FEMALE; FREEZE DRYING; HUMAN; IN VITRO STUDY; MALE; NORMAL HUMAN; OXIDATION; PLASMA; PRIORITY JOURNAL; RADIOACTIVITY; SEX DIFFERENCE; URINALYSIS; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; FECES; FEMALE; GLUCURONIDES; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MOLECULAR STRUCTURE; NICOTINIC AGONISTS; OXIDATION-REDUCTION; OXYGENASES; QUINUCLIDINES; RECEPTORS, NICOTINIC; RECOMBINANT PROTEINS; REFERENCE VALUES; TRITIUM;

EID: 34250768949     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.014449     Document Type: Article

References (23)

1. Baillie TA, Cayen MN, Fouda HG, Gerson RJ, Gree JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
2. Breier A (2005) Developing drugs for cognitive impairment in schizophrenia. Schizophr Bull 31:816-822.
3. Cashman JR (2004) The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov Today 9:574-581.
4. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, and Perry E (1999) Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: α-bungarotoxin and nicotine binding in the thalamus. J Neurochem 73:1590-1597.
5. Fisher MB, Yoon K, Vaughn ML, Strelevitz TJ, and Foti RS (2002) Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance. Drug Metab Dispos 30:1087-1093.
6. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, et al. (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 94:587-592.
7. Green MF and Braff DL (2001) Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry 49:374-384.
8. Hajos M, Hurst RS, Hoffman WE, Krause M, Wall TM, Higdon NR, and Groppi VE (2005) The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312:1213-1222.
9. Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum levels by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413.
10. Holden C (2003) Deconstructing schizophrenia. Science 299:333-335.
11. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, and Burnett AL (2003) Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28:542-551.
12. Lemoine A, Johann M, and Cresteil T (1990) Evidence for the presence of distinct flavin-containing monooxygenases in human tissues. Arch Biochem Biophys 276:336-342.
13. Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R, Perry E, and Nordberg A (2001) Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22:115-126.
14. Meltzer HY and McGurk SR (1999) The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255.
15. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
16. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, et al. (2006) Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630-638.
17. Rettie AE and Fisher MB (1999) Transformation enzymes: oxidative; non-P450, in Handbook of Drug Metabolism (Woolf TF ed), Marcel Dekker, Inc., New York.
18. Sawa A and Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. Science 296:692-695.
19. Shaffer CL, Gunduz M, Thornburgh BA, and Fate GD (2006) Using a tritiated compound to elucidate its preclinical metabolic and excretory pathways in vivo: exploring tritium exchange risk. Drug Metab Dispos 34:1615-1623.
20. Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, Katada J, Hashimoto M, Matsui H, Taki K, et al. (2003) Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 18:48-70.
21. Smith DA and Obach RS (2005) Seeing through the MIST: Abundance versus percentage. Commentary on Metabolites In Safety Testing. Drug Metab Dispos 33:1409-1417.
22. 7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 136:320-327.
23. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobson EJ, Wolfe ML, Groppi VE, et al. (2006) Discovery of PHA-543,613, an agonist of the α7 nicotinic acetylcholine receptor, for the treatment of cognitive deficits in schizophrenia: synthesis and SAR. J Med Chem 49:4425-4436.